DE69634748D1 - Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums - Google Patents

Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums

Info

Publication number
DE69634748D1
DE69634748D1 DE69634748T DE69634748T DE69634748D1 DE 69634748 D1 DE69634748 D1 DE 69634748D1 DE 69634748 T DE69634748 T DE 69634748T DE 69634748 T DE69634748 T DE 69634748T DE 69634748 D1 DE69634748 D1 DE 69634748D1
Authority
DE
Germany
Prior art keywords
treatment
stimulating bone
bone
factor analogue
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69634748T
Other languages
English (en)
Inventor
R Dunstan
Elzbieta Izbicka
Gregory Mundy
Wilson Burgess
C Jaye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CENTELION VITRY SUR SEINE
OSTEOSA LIQUIDATION TRUST SAN
Original Assignee
CENTELION VITRY SUR SEINE
OSTEOSA LIQUIDATION TRUST SAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CENTELION VITRY SUR SEINE, OSTEOSA LIQUIDATION TRUST SAN filed Critical CENTELION VITRY SUR SEINE
Application granted granted Critical
Publication of DE69634748D1 publication Critical patent/DE69634748D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69634748T 1995-05-31 1996-05-29 Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums Expired - Fee Related DE69634748D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/454,964 US5656598A (en) 1994-03-08 1995-05-31 Use of fibroblast growth factors to stimulate bone growth
PCT/US1996/007920 WO1996038167A1 (en) 1995-05-31 1996-05-29 Use of fibroblast growth factors to stimulate bone growth

Publications (1)

Publication Number Publication Date
DE69634748D1 true DE69634748D1 (de) 2005-06-23

Family

ID=23806804

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634748T Expired - Fee Related DE69634748D1 (de) 1995-05-31 1996-05-29 Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums

Country Status (8)

Country Link
US (1) US5656598A (de)
EP (1) EP0830138B1 (de)
JP (1) JP4804598B2 (de)
AT (1) ATE295734T1 (de)
AU (1) AU696460B2 (de)
CA (1) CA2222217C (de)
DE (1) DE69634748D1 (de)
WO (1) WO1996038167A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027630A1 (fr) * 1993-05-31 1994-12-08 Kaken Pharmaceutical Co., Ltd. Preparation de gel a base de gelatine reticulee contenant un facteur de croissance de fibroblaste de base
WO1998039436A2 (en) * 1997-03-03 1998-09-11 Eisai Co., Ltd. Fibroblast growth factor mutein compositions and methods of use therefor
US6274712B1 (en) * 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
CA2266805C (en) * 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6916783B2 (en) * 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
ATE250423T1 (de) 1998-07-13 2003-10-15 Univ Southern California Verfahren zur beschleunigen den zuwachs und heilen von knochen und knorpel
US6551355B1 (en) 1998-08-14 2003-04-22 Cambridge Scientific, Inc. Tissue transplant coated with biocompatible biodegradable polymer
ES2187195T3 (es) * 1998-09-11 2003-05-16 Gerhard Dr Schmidmaier Implantes biologicamente activos.
DE19846685A1 (de) * 1998-10-09 2000-04-13 Richard Markoll Elektromagnetische Stimulierung von Knorpelgewebe
US6231528B1 (en) 1999-01-15 2001-05-15 Jonathan J. Kaufman Ultrasonic and growth factor bone-therapy: apparatus and method
US6660260B1 (en) * 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
CN1196480C (zh) * 2001-07-03 2005-04-13 北京巨能亚太生命科学研究中心 L－苏糖酸钙在制备预防或治疗骨折的药物中的用途
IL149562A0 (en) * 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
US20040043089A1 (en) * 2002-09-04 2004-03-04 Rabie A-Bakr M Buguzhi agent and composition and methods of preparing and administering the same
AU2003279835B2 (en) * 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
WO2004087055A2 (en) * 2003-03-27 2004-10-14 Children's Hospital Medical Center Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
WO2005041998A1 (en) 2003-10-02 2005-05-12 Ali Sadat M Peptide for promoting healing of fractures
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
JPWO2007000884A1 (ja) * 2005-06-29 2009-01-22 国立大学法人金沢大学 骨・関節疾患の予防・治療剤およびそのスクリーニング方法
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
WO2007035778A2 (en) 2005-09-19 2007-03-29 Histogenics Corporation Cell-support matrix and a method for preparation thereof
EP2010193A4 (de) * 2006-04-17 2012-07-25 Hepacore Ltd Verfahren zur knochenregeneration mit endothel-vorläuferzell-zubereitungen
EP2083846B1 (de) * 2006-09-28 2015-07-15 Hepacore Ltd. N-terminale fgf-varianten mit erhöhter rezeptor-selektivität und ihre verwendungen
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US8685107B2 (en) 2007-07-03 2014-04-01 Histogenics Corporation Double-structured tissue implant and a method for preparation and use thereof
CA2717725A1 (en) 2008-03-05 2009-09-11 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US8945511B2 (en) * 2009-06-25 2015-02-03 Paul Weinberger Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3
US20110183311A1 (en) * 2010-01-27 2011-07-28 David Ho Dry platelet preparations for use in diagnostics
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
EP3532111B1 (de) * 2016-10-26 2021-01-20 Biointelligence Systems S.L. Bioaktive knochenzusammensetzung und verwendungen davon
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
EP3886879A4 (de) 2018-11-30 2022-12-07 Cellphire Inc. Thrombozyten als freisetzungsmittel
AU2019387368A1 (en) 2018-11-30 2021-06-17 Cellphire, Inc. Platelets as delivery agents
SG11202112054WA (en) 2019-05-03 2021-11-29 Cellphire Inc Materials and methods for producing blood products
WO2021034719A1 (en) 2019-08-16 2021-02-25 Cellphire, Inc. Thrombosomes as an antiplatelet agent reversal agent
CA3170196A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets
CN117582485B (zh) * 2023-11-15 2024-06-07 湛江中心人民医院 方格星虫三肽在制备骨质疏松药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4868113A (en) * 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US5223483A (en) * 1987-10-22 1993-06-29 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
US5312911A (en) * 1987-10-22 1994-05-17 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
AU629316B2 (en) * 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
DE69211723T2 (de) * 1991-02-15 1996-10-31 Takeda Chemical Industries Ltd Mit einem Zellwachstumsfaktor bewirkte Anregung von Wachstum im Knocheninneren
WO1995024211A1 (en) * 1994-03-08 1995-09-14 Osteosa, Inc. Use of fibroblast growth factors to stimulate bone growth

Also Published As

Publication number Publication date
WO1996038167A1 (en) 1996-12-05
CA2222217C (en) 2010-09-14
ATE295734T1 (de) 2005-06-15
EP0830138B1 (de) 2005-05-18
CA2222217A1 (en) 1996-12-05
AU696460B2 (en) 1998-09-10
AU6146496A (en) 1996-12-18
JPH11506446A (ja) 1999-06-08
JP4804598B2 (ja) 2011-11-02
EP0830138A1 (de) 1998-03-25
EP0830138A4 (de) 2000-10-25
US5656598A (en) 1997-08-12

Similar Documents

Publication Publication Date Title
DE69634748D1 (de) Verwendung von fibroblasten-wachstumsfaktor analogen zur stimulation des knochenwachstums
DE69533176D1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
Isaksson et al. Maxillary alveolar ridge augmentation with onlay bone-grafts and immediate endosseous implants
Rutherford et al. Use of bovine osteogenic protein to promote rapid osseointegration of endosseous dental implants.
DE69427947D1 (de) Verwendung von teilchen eines bioverträglichen und bioresorbierbaren kalziumsalzes als wirkstoff in der herstellung eines arzneimittels zur lokalen behandlung von entkalkungskrankheiten
DE69813908D1 (de) Verwendung von kreatinsubstanzen zur behandlung von knochen- und knorpelzellen und geweben
Mao et al. Strain induced osteogenesis of the craniofacial suture upon controlled delivery of low-frequency cyclic forces
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ten Bruggenkate et al. Clinical evaluation of the ITI (F-type) hollow cylinder implant
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
NO980375L (no) Humant MP52 Arg protein
WO2004019873A3 (en) Methods of promoting osteogenesis
DE69133074T2 (de) Einen basischen Fibroblastwachstumsfaktor enthaltende Mittel zur Behandlung von Knochenkrankheiten
EP0585801A3 (en) Bone-related cadherin-like protein and process for its production
KR950703993A (ko) 치주 조직 질환 치료제(periodonal disease remedy)
Stalnecker et al. Electrical stimulation of onlay bone grafts
Karimovna et al. Improvement of methods of alveoplasty of anterior upper jaw in case of atrophy
ATE206930T1 (de) Verwendung von osteoblast-proliferationsfaktor
TW224943B (en) The pharmaceutical composition for the stimulation of bone formation
Nickenig et al. Indications and surgical technique for distraction osteogenesis of the alveolar bone for augmentation prior to insertion of dental implants
Friedlander et al. Selective resection of the circumoral musculature for enhancement of mandibular denture stability
MD899G2 (ro) Procedeu de activizare a osteogenezei reparatorii
UA33571A (uk) Спосіб лікування травматичного перелому нижньої щелепи

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee